Chimeric antigen receptor (CAR) T cells face a unique set of challenges in the context of solid tumors. To induce a favorable clinical outcome, CAR T cells have to surmount a series of increasingly arduous tasks. First, they have to be made specific for an antigen whose expression clearly demarcates tumor from normal tissue. Then, they must be able to home and penetrate the desmoplastic stroma that surrounds the tumor. Once within the tumor, they must expand, persist, and mediate cytotoxicity in a hostile milieu largely composed of immunosuppressive modulators. Whereas a seemingly herculean task, all of the aforementioned requirements can potentially be met effectively through both intrinsic and/or extrinsic modifications of CAR T cells. In this review, we delineate the barriers imposed by solid tumors on CARs and strategies that have and should be undertaken to improve therapeutic response.
T cells, the armed forces of our immune repertoire, are constantly coursing through the bloodstream on the lookout for foreign antigens. On encountering a solid tumor, a complex and dynamic mass composed of rogue host cells, T cells often fail to mount an effective response. Even when tumor responsive T cells extravasate to tumor sites, they are faced with a barrage of immunosuppressive factors that render them nonresponsive. Thus, even the most adroit natural eliminator is exhausted in the tumor environment. Fortunately, there exist genetic approaches that can reprogram ordinary circulating T cells to highly specific slayers of cancer cells. [1] [2] [3] Genetically modifying T cells with chimeric antigen receptors (CARs) is the most commonly used approach to generate tumorspecific T cells. 1 As outlined in detail in other contributions to this themed journal issue, CARs consist of an ectodomain, commonly derived from a single-chain variable fragment (scFv), a hinge, a transmembrane domain, and an endodomain with 1 (first-generation), 2 (second-generation), or 3 (third-generation) signaling domains derived from CD3ζ and/or costimulatory molecules. 4 Whereas CAR T cells have been successful in earlyphase clinical studies treating CD19-positive hematological malignancies, 5-8 the success of CARs in the purview of solid tumors has been greatly hampered by the lack of unique tumor-associated antigens, inefficient homing of T cells to tumor sites, and the immunosuppressive microenvironment of solid tumors. In this review, we delineate the barriers imposed by solid tumors on CARs and strategies that have and should be undertaken to improve therapeutic response.
SOLID TUMOR ANTIGENS
Tumor-associated antigens can be divided into several groups including antigens that (1) contain novel peptide sequences due to gene mutation, (2) are expressed in a tissue/lineage specific fashion, (3) are normally expressed during fetal development or at immunoprivileged sites, or (4) are expressed at higher-thannormal levels on tumor cells compared to nonmalignant host cells.
Mutated Antigens
Ideally, the targeted antigen should contain a novel peptide sequence, limiting its expression to tumor cells. One example is a splice variant of the epidermal growth factor receptor (EGFRvIII). 9 Other antigens that may provide some target exclusivity include those with altered posttranslational modifications or those that present conformational epitopes unique to the tumor microenvironment. Examples of the former include abnormal tumorspecific glycosylation patterns of MUC-1, 10 and examples of the latter include conformational EGFR and erythropoietin-producing hepatocellular A2 receptor epitopes. 11, 12 Tissue/Lineage Antigens Tissue/Lineage-restricted antigens by definition show restrictive expression patterns and may seem particularly attractive. Whereas tissue expendability is acceptable or correctable in certain conditions like B-cell aplasia with CD19 CAR T cells, the function of most solid organs cannot be readily replaced. However, tissue-specific antigens of organs that are dispensable such as prostate-specific cancer antigen 13 are actively being explored.
Developmental Antigens
Antigens expressed during fetal development or at immunoprivileged sites such as melanoma-associated antigen family members or NY-ESO-1 are actively being targeted with αß T-cell receptors. 14, 15 However, most of these antigens are in cytoplasm, making them inaccessible to scFv-based CARs that recognize antigens expressed on the cell surface. However, scFv have been developed that recognize peptide derived from cytoplasmic proteins in the context of human leukocyte antigen molecule, making them "CAR targetable." 16 
Overexpressed Antigens
Most targeted antigens are only overexpressed in comparison to normal tissues, raising concerns about "on target/off tumor" adverse effects, which in most cases cannot be adequately assessed in murine models. Nevertheless, a broad array of overexpressed solid tumor antigens has been targeted in preclinical models with CAR T cells (Table 1) , and several clinical studies have been conducted ( Table 2 ).
Targeting Multiple Antigens
In contrast to conventional T cells that only recognize single antigens, CAR T cells can be genetically modified to recognize multiple antigens, which should allow the recognition of unique antigen expression patterns on tumor cells. One example includes "split signal CARs" that limit full T-cell activation to tumors expressing multiple antigens. [17] [18] [19] Other strategies to target multiple antigens include tandem CARs, which contain ectodomains with 2 scFvs, 20 and so-called universal ectodomain CARs that incorporate avidin or a fluorescein isothiocyanatespecific scFv to recognize tumor cells that have been incubated with tagged monoclonal antibodies. 21, 22 Targeting multiple antigens should also limit the risk of immune escape. 23 In summary, numerous solid tumor antigens are being actively explored for CAR T-cell therapy; however, only few are uniquely tumor specific. Whereas genetic approaches can be used to increase specificity, there is a growing exigency to discover novel tumor antigens as CAR T cells become more potent. 24 
CLINICAL TRIALS WITH SOLID TUMOR-SPECIFIC CAR T CELLS
Preclinical studies have targeted a broad array of solid tumor antigens with CAR T cells ( Table 1 ). Antigens currently targeted in clinical studies include carbonic anhydrase IX (CAIX), CD171, folate receptor alpha (FR-α), GD2, human epidermal growth factor receptor 2 (HER2), mesothelin, EGFRvIII, fibroblast activation protein (FAP), carcinoembryonic antigen (CEA), and vascular endothelial growth factor receptor 2 (VEGF-R2) ( Table 2 ). Most clinical studies so far have used first-generation CAR T cells, and whereas the studies have demonstrated feasibility, the clinical results have been, in general, disappointing. [25] [26] [27] Nevertheless, these studies gave important insights into CAR T-cell biology. Lamers et al 25 infused patients with renal carcinoma with polyclonal T cells expressing a first-generation CAIX-specific CAR and observed on target/off cancer adverse effects, as well as the development of anti-CAR immune responses resulting in limited T-cell persistence. Subsequently, pretreatment with CAIX monoclonal antibodies before CAR T-cell transfer prevented hepatitis and abrogated the induction of anti-CAR immune responses. 26 Limited CAR T-cell persistence was also observed in neuroblastoma patients, who received CD8-positive T-cell clones expressing first-generation CD171-specifc CARs, 27 and in patients with ovarian cancer who received folate receptor α-specific CAR T cells. 28 The latter study also highlighted that T-cell homing to solid tumor sites is limited, which at least in preclinical studies can be overcome by genetically modifying T cells with chemokine receptors. 29, 30 The most promising results (including complete responses) were achieved by Pule et al with first-generation CARs directed to GD2, which were expressed in Epstein-Barr virusspecific T cells. 31, 32 Human epidermal growth factor receptor 2 has been targeted with second-and third-generation CAR T cells. 33, 34 One patient developed acute respiratory distress syndrome and died after receiving lymphodepleting chemotherapy, and 10 10 T cells expressing a third-generation HER2-specific CAR in combination with IL-2. 33 In a second study, up to 10 8 /m 2 T cells expressing a secondgeneration HER2-CAR T cells have been infused. Whereas no overt toxicities were observed, the antitumor activity was limited. Clinical studies with mesothelin-, EGFRvIII-, VEGF-R2-, GD2-, and FAP-specific second-or third-generation CAR T cells are in progress or will be soon initiated ( Table 2 ).
GENETIC MODIFICATION TO ENHANCE CAR T-CELL FUNCTION
Strategies to improve the antitumor activity of CAR T cells include the provision of costimulation, the careful selection of T-cell subsets in which to express CARs, and additional genetic modification to enhance CAR T-cell function. We will focus our discussion on additional genetic modifications (Table 3) , as the first 2 strategies are being discussed in detail in other contributions to this themed journal issue. The solid tumor microenvironment is extremely inhospitable and capable of inducing anergy in CAR T cells. T cells must therefore come armed with countermeasures to thrive in an environment that is replete with immunosuppressive cytokines, regulatory modulators, and coinhibitory receptors. 35 Whereas inclusion of costimulatory signaling domains in the endodomain of CARs can render CAR T cells resistant to inhibitory T cells and/or TGFβ, additional genetic modification strategies are actively being explored to enhance their function. Transgenic expression of cytokines such as IL-15 36, 37 improves CAR T-cell expansion and persistence in vivo and renders T cells resistant to the inhibitory effects of Tregs. 38 Alternatively, transgenic expression of IL-12 in CAR T cells reverses the immunosuppressive tumor environment. 39 Whereas there are safety concerns with regard to constitutive IL-12 expression, inducible expression systems are available to restrict IL-12 production to activated T cells at the tumor site. 40 Conversely, CAR T cells can be engineered to resist the effects of immunosuppressive cytokines that can inhibit their effector functions. Transforming growth factor β is widely used by tumors as an immune evasion strategy, 41 as it limits effector T-cell function and activates Tregs. These detrimental effects of TGFβ can be overcome by expressing a dominant negative TGFβ receptor II, 42, 43 and this approach is currently being tested in clinical trials. 44 Chimeric antigen receptor T cells can also be genetically engineered to actively benefit from the inhibitory signals generated by the tumor environment, by expressing chimeric receptors that convert inhibitory signals provided by TGFβ, IL4, or programmed death 1 into stimulatory signals. [45] [46] [47] [48] Lastly, silencing genes that render T cells susceptible to inhibitory signals in the tumor microenvironment may also improve CAR T-cell function 49 or the transgenic expression of constitutively active signaling molecules. 50 
TARGETING THE TUMOR STROMA WITH CAR T CELLS
Most solid tumors have a stromal compartment that supports tumor growth directly through paracrine secretion of cytokines, growth factors, and provision of nutrients and contributes to tumor-induced immunosuppression. 51 For example, T cells expressing CARs specific for FAP expressed on cancer-associated fibroblasts has potent antitumor effects. 52 To prevent on target/off tumor toxicity, 53, 54 transient expression of FAP CAR-T cells may be sufficient to weaken the desmoplastic stroma and allow infiltration of tumor-specific CAR T cells. Targeting the tumor vasculature with CARs is another attractive strategy. 55, 56 Whereas the initial CAR ectodomain was based on VEGF to target VEGF receptor 2 (VEGF-R2), more recent studies have used a VEGF receptor 2-specific scFv, and targeting the tumor vasculature in addition to tumor cells synergized in inducing tumor regression in preclinical models. 56 
COMBINATORIAL CAR T-CELL THERAPY
Combining CAR T cells with other therapies offer the potential to improve antitumor effects. For example, the solid tumor microenvironment abounds in coinhibitory receptors like cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 that are known to limit the efficacy of any directly stimulatory strategy. 57 Systemic administration of antagonists (blocking antibodies) to these coinhibitory receptors resulted in remarkable response rates even in refractory solid tumors, [58] [59] [60] and combining blocking antibodies with CAR T cells should boost antitumor effects. Other strategies include epigenetic modifiers that up-regulate the expression of tumor-associated antigens 61 or the use of targeted therapies that inhibit tumor cell growth but are not detrimental to T cells. 62 
CONCLUSIONS
The ultimate goal of CAR T-cell therapy for solid tumors is to be curative. This requires the development of a potent product that can withstand and thrive in the solid tumor microenvironment. Significant strides have been made toward this end in preclinical studies. Whereas the options are varied, a judicious assessment of a given solid tumor and its microenvironment can help narrow them down to those that would render CAR T cells most successful in inducing a therapeutic response. Clinical trials comparing different genetic modification strategies 63 will be crucial in the future to optimize CAR T cells, transitioning CAR T cells from merely promising to being effective treatments for solid tumors.
